The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials-Reference-Cited by-同舟云学术

The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials

Published:2022-01 Issue: Volume:169 Page:103540
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Fazzari Francesco G.T.^ORCID,Rose Foster,Pauls Mehrnoosh,Guay Evelyne^ORCID,Ibrahim Mohammed F.K.,Basulaiman Bassam^ORCID,Tu Megan,Hutton Brian^ORCID,Nicholas Garth^ORCID,Ng Terry L.^ORCID

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference98 articles.

1. AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer;AbbVie,2021

2. Biomarker-based adaptive trials for patients with glioblastoma—lessons from I-SPY 2;Alexander;Neuro-Oncology,2013

3. Adaptive global innovative learning environment for glioblastoma: GBM AGILE;Alexander;Clin. Cancer Res.,2018

4. Reoperation in the treatment of recurrent intracranial malignant gliomas;Ammirati;Neurosurgery,1987

5. ACTR-61. A randomized phase 2 trial of cediranib in combination with olaparib versus bevacizumab in patients with recurrent glioblastoma;Arrillaga-Romany;Neuro-Oncology,2019

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanistic Insights on Metformin and Arginine Implementation as Repurposed Drugs in Glioblastoma Treatment;International Journal of Molecular Sciences;2024-08-30

2. Systemic and local immunosuppression in glioblastoma and its prognostic significance;Frontiers in Immunology;2024-02-28

3. Current and Future Drugs for Brain Tumors Treatment;Advanced Imaging and Therapy in Neuro-Oncology;2024

4. Management and outcomes of glioblastoma: 20‐year experience in a single Australian institution;Journal of Medical Imaging and Radiation Oncology;2023-11-24

5. The impact of survivorship bias in glioblastoma research;Critical Reviews in Oncology/Hematology;2023-08